Publications
T
Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.,
Lim, Shion A., Zhou Jie, Martinko Alexander J., Wang Yung-Hua, Filippova Ekaterina V., Steri Veronica, Wang Donghui, Remesh Soumya G., Liu Jia, Hann Byron, et al.
, J Clin Invest, 2022 Feb 15, Volume 132, Issue 4, (2022)
V
Visualization of arrestin recruitment by a G-protein-coupled receptor,
Shukla, A. K., Westfield G. H., Xiao K., Reis R. I., Huang L. Y., Tripathi-Shukla P., Qian J., Li S., Blanc A., Oleskie A. N., et al.
, Nature, Volume 512, Number 7513, p.218-22, (2014)
Pages
- « first
- ‹ previous
- 1
- 2
- 3
- 4
Publications
- Characterization of synthetic antigen binding fragments targeting Toc75 for the isolation of TOC in A. thaliana and P. sativum.
- Development of a universal nanobody-binding Fab module for fiducial-assisted cryo-EM studies of membrane proteins.
- Development, structure, and mechanism of synthetic antibodies that target claudin and Clostridium perfringens enterotoxin complexes.
- Engineering of a synthetic antibody fragment for structural and functional studies of K+ channels.
- Isoform- and ligand-specific modulation of the adhesion GPCR ADGRL3/Latrophilin3 by a synthetic binder.
- Quaternary structure independent folding of voltage-gated ion channel pore domain subunits.
- Structural basis for assembly and lipid-mediated gating of LRRC8A:C volume-regulated anion channels.
- Structure of an AMPK complex in an inactive, ATP-bound state.
- Structure of human NTCP reveals the basis of recognition and sodium-driven transport of bile salts into the liver.
- Structure, sequon recognition and mechanism of tryptophan C-mannosyltransferase.
- Structures of ABCB4 provide insight into phosphatidylcholine translocation.
- Structures of atypical chemokine receptor 3 reveal the basis for its promiscuity and signaling bias.
- Synthetic Antibodies Detect Distinct Cellular States of Chromosome Passenger Complex Proteins.
- Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers.